The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Going viral with cancer immunotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Self-citationNecroptosis: The Release of Damage-Associated Molecular Patterns and Its Physiological Relevance
Kaczmarek, A., Vandenabeele, P., & Krysko, D. V. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.003 · Cited by 1,411
Cited by
Management of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
Self-citationVaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Oncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Self-citationBiomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Wen, A. M., & Steinmetz, N. F. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00287g · Cited by 379
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2017) · Nature Communications · doi:10.1038/ncomms14754 · Cited by 350
Biomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2020) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 328
Oncolytic virus immunotherapy: future prospects for oncology
Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0458-z · Cited by 313
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
Bourgeois-Daigneault, M.-C., Roy, D. G., Aitken, A. S., El Sayes, N., Martin, N. T., Varette, O., Falls, T., St-Germain, L. E., Pelin, A., Lichty, B. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1641 · Cited by 293
Self-citationWatanabe, K., Luo, Y., Da, T., Guedan, S., Ruella, M., Scholler, J., Keith, B., Young, R. M., Engels, B., Sorsa, S., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99573 · Cited by 283
Geletneky, K., Hajda, J., Angelova, A. L., Leuchs, B., Capper, D., Bartsch, A. J., Neumann, J.-O., Schöning, T., Hüsing, J., Beelte, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.016 · Cited by 260
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity
Ilkow, C. S., Marguerie, M., Batenchuk, C., Mayer, J., Ben Neriah, D., Cousineau, S., Falls, T., Jennings, V. A., Boileau, M., Bellamy, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3848 · Cited by 165
Self-citationChon, H. J., Lee, W. S., Yang, H., Kong, S. J., Lee, N. K., Moon, E. S., Choi, J., Han, E. C., Kim, J. H., Ahn, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1932 · Cited by 158
(2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2165 · Cited by 127
Liu, Z., Ravindranathan, R., Li, J., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1091554 · Cited by 113
Immunotherapy in Glioblastoma: A Clinical Perspective
Desbaillets, N., & Hottinger, A. F. (2021) · Cancers · doi:10.3390/cancers13153721 · Cited by 31
Metadata
- Authors
- Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C.
- Venue
- Nature Reviews Cancer
- Published
- 2014-07-03
- Volume
- 14
- Issue
- 8
- Pages
- 559-567
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2011513757
- Cited by
- 581
- References
- 111
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.